Archive for the ‘Fuad El-Hibri’ Category

Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed – Indolent Lymphoma

ROCKVILLE, Md., Aug 17, 2011 –
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin’s B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical(TM) protein therapeutic in development for [...]

Emergent BioSolutions to Present at Wedbush 2011 Life Sciences Conference

ROCKVILLE, Md., Aug 09, 2011 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Wedbush 2011 Life Sciences Conference in New York on Wednesday, August 17, 2011 at 10:00 AM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate [...]

Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax

ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June 23rdthat the Singapore Health Sciences Authority (HSA) has approved Emergent’s product license application for the marketing and sale of BioThrax(R) (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.
“Emergent is [...]

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors

ROCKVILLE, Md., Jun 13, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its Chairman and Chief Executive Officer, Fuad El-Hibri, has been appointed to serve on the Board of Directors of the U.S. Chamber of Commerce. The U.S. Chamber of Commerce is the world’s largest business federation representing the interests of more [...]

Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation

ROCKVILLE, Md., Jun 09, 2011 — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its investigational anthrax vaccine, NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The vaccine candidate, also known as AV7909, consists of BioThrax(R) (Anthrax Vaccine Adsorbed) in combination with [...]

Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule

ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the company’s contract (200-2009-30162) originally written to supply 14.5 million doses of BioThrax to the Strategic National Stockpile. This marks the largest [...]

Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference

ROCKVILLE, Md., May 25, 2011 — Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Jefferies 2011 Global Healthcare Conference in New York on Tuesday, June 7, 2011 at 1:15 PM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate [...]

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress

ROCKVILLE, Md., Apr 12, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress. The ViE awards showcase excellence and honor accomplishments of both individuals [...]

Emergent BioSolutions Reports Financial Results for Full Year 2010

2010 revenues of $286.2 million
2010 net income of $51.7 million, or $1.63 per share, representing ninth consecutive year of profitability
2010 cash, investments and accounts receivable balance of $210.4 million
2011 forecast reaffirmed: total revenues of $320 to $340 million and net income of $35 to $45 million

Emergent BioSolutions Inc. (NYSE: EBS) announced on 10 March its [...]

Emergent BioSolutions to Present Today at Needham & Company Healthcare Conference

Emergent BioSolutions Inc. (NYSE: EBS) will be webcasting its presentation at the 10th Annual Needham & Company Healthcare Conference in New York on Tuesday, April 5, 2011 at 8:00 AM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate overview, which may include a discussion of [...]